

On-line Table 1: Uni- and multivariate analyses of factors associated with antiplatelet response to clopidogrel						
	Total	% inhibition		P Value		Odds Ratio (95% CI)
		<40%	≥40%	Univariate	Multivariate	
Number (%)	98	42 (42.9)	56 (57.1)			
Age (years)	59 ± 16	61 ± 14	58 ± 17	.275	.674	
Women (%)	72 (73.5)	27 (64.3)	45 (80.4)	.105	.894	
Weight (kg)	75.0 ± 17.8	81.9 ± 19.1	69.9 ± 15.1	.001	.01	0.956 (0.924–0.989)
Platelets ($\times 10^3/\mu\text{L}$)	287.3 ± 88.6	258.3 ± 60.2	309.0 ± 100.2	.002	.017	1.009 (1.002–1.016)
Hematocrit (%)	39.8 ± 3.7	40.6 ± 4.1	39.2 ± 3.3	.053	.587	
Risk factors						
Hypertension (%)	54 (55.1)	26 (61.9)	28 (50.0)	.306	.855	
Diabetes (%)	20 (20.4)	9 (21.4)	11 (19.6)	1	NA	
Hyperlipidemia (%)	39 (39.8)	15 (35.7)	24 (42.9)	.535	NA	
Smoking (%)	25 (25.5)	11 (26.2)	14 (25.0)	1	NA	
CAD or PAD (%)	22 (22.4)	10 (23.8)	12 (21.4)	.811	NA	
Lesions						
Aneurysmal disease (%)	60 (61.2)	24 (57.1)	36 (64.3)	.533	NA	
SAH (%)	4 (4.1)	2 (50)	2 (50)	1	NA	
Atherosclerotic disease (%)	33 (33.7)	16 (38.1)	17 (30.4)	.518	NA	
Duration of antiplatelet therapy						
<1 day	5 (5.1%)	2 (40.0%)	3 (60.0%)	.126	.06	
1 day	8 (8.2%)	3 (37.5%)	5 (62.5%)			
2–4 days	5 (5.1%)	5 (100%)	1 (0%)			
5–10 days	49 (50.0%)	20 (40.8%)	29 (59.2%)			
>10 days	31 (31.6%)	12 (38.7%)	19 (61.3%)			

Note:—CI indicates confidence interval; NA, not applicable; CAD, coronary artery disease; PAD, peripheral artery disease; SAH, subarachnoid hemorrhage.